ASPEN PHARMACARE HOLDINGS LIMITED - Further Announcement Relating To The Acquisition By Aspen Of The Glaxosmithkline Groups (Gsk) Arixtra And Fraxipa

Further Announcement Relating To The Acquisition By Aspen Of The Glaxosmithkline Group’s (“Gsk”) Arixtra And Fraxipa

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
(“Aspen Holdings”)



FURTHER ANNOUNCEMENT RELATING TO THE ACQUISITION BY ASPEN OF THE GLAXOSMITHKLINE
GROUP’S (“GSK”) ARIXTRA AND FRAXIPARINE/FRAXODI BRANDS AND BUSINESS WORLDWIDE

Shareholders are referred to the terms announcement and circular released by Aspen Holdings, on
30 September and 9 October 2013 respectively, wherein it was confirmed that the Aspen Group (“Aspen”)
had entered into an agreement with GSK in terms whereof Aspen would acquire:

    -   “the Business” - the business carried on by GSK in respect of the commercialisation of Arixtra,
        Fraxiparine and Fraxodi trademarks, as marketed by GSK or its distributors in the world (“the
        Relevant Markets”) except for the People’s Republic of China (including its Special Administrative
        Regions, Hong Kong and Macau), India and Pakistan – (collectively, “the Excluded Territories”) with
        effect from 1 January 2014, subject to certain conditions precedent being met; and

    -   “the Manufacturing Business” - the business carried out at the Notre Dame de Bondeville
        manufacturing site (“the Site”) relating to the manufacture of the Products for commercialisation
        in the Relevant Markets and Excluded Territories and the manufacture of diluents for GSK, during
        the second quarter of 2014, subject to certain conditions precedent being met.

Shareholders are advised that all conditions precedent have been met in respect of the acquisition of the
Business and the Manufacturing Business. As a result the acquisition of the Business has completed with
effect from today and all of the material commercial operations related to the Business will therefore
transfer to Aspen on 1 January 2014. The acquisition of the Manufacturing Business is expected to
complete during the second quarter of 2014.

Durban
31 December 2013

Underwriters
The Standard Bank of South Africa Limited
Bank of America, N.A.

Mandated Lead Arrangers and Bookrunners
The Standard Bank of South Africa Limited
Banc of America Securities Limited

Sponsor:
Investec Bank Limited

Date: 31/12/2013 11:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.